nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Mycophenolic acid—psoriasis	0.405	0.642	CbGbCtD
Raltegravir—UGT1A1—Mycophenolate mofetil—psoriasis	0.226	0.358	CbGbCtD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL20—psoriasis	0.00316	0.162	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—HCAR2—psoriasis	0.00193	0.099	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00153	0.0787	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00119	0.061	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—HCAR2—psoriasis	0.00117	0.06	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCL20—psoriasis	0.001	0.0514	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—psoriasis	0.000853	0.0438	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000797	0.0409	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—HCAR2—psoriasis	0.00066	0.0339	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL20—psoriasis	0.000607	0.0311	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HCAR2—psoriasis	0.0006	0.0308	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00052	0.0267	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP2S1—psoriasis	0.000467	0.024	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000461	0.0236	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HCAR2—psoriasis	0.000354	0.0182	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCL20—psoriasis	0.000343	0.0176	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000321	0.0165	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL20—psoriasis	0.000312	0.016	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TAGAP—psoriasis	0.000307	0.0158	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—psoriasis	0.000271	0.0139	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFA—psoriasis	0.00026	0.0133	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000224	0.0115	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000215	0.011	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000193	0.00992	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL20—psoriasis	0.000184	0.00944	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—psoriasis	0.000164	0.00841	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000145	0.00743	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SOCS1—psoriasis	0.000101	0.0052	CbGpPWpGaD
Raltegravir—Feeling abnormal—Cyclosporine—psoriasis	9.97e-05	0.000286	CcSEcCtD
Raltegravir—Insomnia—Prednisolone—psoriasis	9.96e-05	0.000285	CcSEcCtD
Raltegravir—Alopecia—Prednisone—psoriasis	9.95e-05	0.000285	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—psoriasis	9.92e-05	0.000284	CcSEcCtD
Raltegravir—Gastrointestinal pain—Cyclosporine—psoriasis	9.9e-05	0.000283	CcSEcCtD
Raltegravir—Dizziness—Mycophenolic acid—psoriasis	9.89e-05	0.000283	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—psoriasis	9.89e-05	0.000283	CcSEcCtD
Raltegravir—Paraesthesia—Prednisolone—psoriasis	9.89e-05	0.000283	CcSEcCtD
Raltegravir—Mental disorder—Prednisone—psoriasis	9.87e-05	0.000283	CcSEcCtD
Raltegravir—Erythema—Prednisone—psoriasis	9.81e-05	0.000281	CcSEcCtD
Raltegravir—Malnutrition—Prednisone—psoriasis	9.81e-05	0.000281	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Hydrocortisone—psoriasis	9.8e-05	0.000281	CcSEcCtD
Raltegravir—Hyperhidrosis—Triamcinolone—psoriasis	9.79e-05	0.00028	CcSEcCtD
Raltegravir—Feeling abnormal—Mycophenolate mofetil—psoriasis	9.73e-05	0.000279	CcSEcCtD
Raltegravir—Insomnia—Hydrocortisone—psoriasis	9.73e-05	0.000279	CcSEcCtD
Raltegravir—Hypertension—Dexamethasone—psoriasis	9.72e-05	0.000278	CcSEcCtD
Raltegravir—Hypertension—Betamethasone—psoriasis	9.72e-05	0.000278	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—TYK2—psoriasis	9.66e-05	0.00496	CbGpPWpGaD
Raltegravir—Paraesthesia—Hydrocortisone—psoriasis	9.66e-05	0.000277	CcSEcCtD
Raltegravir—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.66e-05	0.000276	CcSEcCtD
Raltegravir—Urticaria—Cyclosporine—psoriasis	9.62e-05	0.000275	CcSEcCtD
Raltegravir—Myalgia—Dexamethasone—psoriasis	9.59e-05	0.000275	CcSEcCtD
Raltegravir—Myalgia—Betamethasone—psoriasis	9.59e-05	0.000275	CcSEcCtD
Raltegravir—Abdominal pain—Cyclosporine—psoriasis	9.57e-05	0.000274	CcSEcCtD
Raltegravir—Body temperature increased—Cyclosporine—psoriasis	9.57e-05	0.000274	CcSEcCtD
Raltegravir—Anxiety—Betamethasone—psoriasis	9.55e-05	0.000274	CcSEcCtD
Raltegravir—Anxiety—Dexamethasone—psoriasis	9.55e-05	0.000274	CcSEcCtD
Raltegravir—Vomiting—Mycophenolic acid—psoriasis	9.51e-05	0.000272	CcSEcCtD
Raltegravir—Discomfort—Betamethasone—psoriasis	9.47e-05	0.000271	CcSEcCtD
Raltegravir—Discomfort—Dexamethasone—psoriasis	9.47e-05	0.000271	CcSEcCtD
Raltegravir—Dyspepsia—Hydrocortisone—psoriasis	9.47e-05	0.000271	CcSEcCtD
Raltegravir—Rash—Mycophenolic acid—psoriasis	9.43e-05	0.00027	CcSEcCtD
Raltegravir—Dermatitis—Mycophenolic acid—psoriasis	9.42e-05	0.00027	CcSEcCtD
Raltegravir—Pain—Prednisolone—psoriasis	9.42e-05	0.00027	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—psoriasis	9.41e-05	0.00027	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NDUFA5—psoriasis	9.39e-05	0.00482	CbGpPWpGaD
Raltegravir—Urticaria—Mycophenolate mofetil—psoriasis	9.38e-05	0.000269	CcSEcCtD
Raltegravir—Headache—Mycophenolic acid—psoriasis	9.37e-05	0.000268	CcSEcCtD
Raltegravir—Decreased appetite—Hydrocortisone—psoriasis	9.35e-05	0.000268	CcSEcCtD
Raltegravir—Abdominal pain—Mycophenolate mofetil—psoriasis	9.33e-05	0.000267	CcSEcCtD
Raltegravir—Body temperature increased—Mycophenolate mofetil—psoriasis	9.33e-05	0.000267	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—psoriasis	9.3e-05	0.000266	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.29e-05	0.000266	CcSEcCtD
Raltegravir—Fatigue—Hydrocortisone—psoriasis	9.27e-05	0.000266	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—psoriasis	9.26e-05	0.00475	CbGpPWpGaD
Raltegravir—Urethral disorder—Methotrexate—psoriasis	9.23e-05	0.000264	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.23e-05	0.000264	CcSEcCtD
Raltegravir—Pain—Hydrocortisone—psoriasis	9.2e-05	0.000263	CcSEcCtD
Raltegravir—Insomnia—Triamcinolone—psoriasis	9.16e-05	0.000262	CcSEcCtD
Raltegravir—Infection—Dexamethasone—psoriasis	9.13e-05	0.000261	CcSEcCtD
Raltegravir—Infection—Betamethasone—psoriasis	9.13e-05	0.000261	CcSEcCtD
Raltegravir—Ill-defined disorder—Prednisone—psoriasis	9.1e-05	0.000261	CcSEcCtD
Raltegravir—Paraesthesia—Triamcinolone—psoriasis	9.1e-05	0.00026	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisolone—psoriasis	9.08e-05	0.00026	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—psoriasis	9.07e-05	0.00026	CcSEcCtD
Raltegravir—Anaemia—Prednisone—psoriasis	9.06e-05	0.00026	CcSEcCtD
Raltegravir—Nervous system disorder—Dexamethasone—psoriasis	9.01e-05	0.000258	CcSEcCtD
Raltegravir—Nervous system disorder—Betamethasone—psoriasis	9.01e-05	0.000258	CcSEcCtD
Raltegravir—Agitation—Prednisone—psoriasis	9.01e-05	0.000258	CcSEcCtD
Raltegravir—Thrombocytopenia—Dexamethasone—psoriasis	9e-05	0.000258	CcSEcCtD
Raltegravir—Thrombocytopenia—Betamethasone—psoriasis	9e-05	0.000258	CcSEcCtD
Raltegravir—Hypersensitivity—Cyclosporine—psoriasis	8.92e-05	0.000255	CcSEcCtD
Raltegravir—Dyspepsia—Triamcinolone—psoriasis	8.92e-05	0.000255	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—psoriasis	8.9e-05	0.000255	CcSEcCtD
Raltegravir—Nausea—Mycophenolic acid—psoriasis	8.89e-05	0.000254	CcSEcCtD
Raltegravir—Hyperhidrosis—Betamethasone—psoriasis	8.88e-05	0.000254	CcSEcCtD
Raltegravir—Hyperhidrosis—Dexamethasone—psoriasis	8.88e-05	0.000254	CcSEcCtD
Raltegravir—Feeling abnormal—Hydrocortisone—psoriasis	8.86e-05	0.000254	CcSEcCtD
Raltegravir—Malaise—Prednisone—psoriasis	8.84e-05	0.000253	CcSEcCtD
Raltegravir—Vertigo—Prednisone—psoriasis	8.81e-05	0.000252	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—psoriasis	8.8e-05	0.000252	CcSEcCtD
Raltegravir—Gastrointestinal pain—Hydrocortisone—psoriasis	8.8e-05	0.000252	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—psoriasis	8.78e-05	0.000251	CcSEcCtD
Raltegravir—Urticaria—Prednisolone—psoriasis	8.75e-05	0.000251	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—psoriasis	8.74e-05	0.00025	CcSEcCtD
Raltegravir—Fatigue—Triamcinolone—psoriasis	8.73e-05	0.00025	CcSEcCtD
Raltegravir—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.7e-05	0.000249	CcSEcCtD
Raltegravir—Asthenia—Cyclosporine—psoriasis	8.68e-05	0.000249	CcSEcCtD
Raltegravir—Pain—Triamcinolone—psoriasis	8.66e-05	0.000248	CcSEcCtD
Raltegravir—Pruritus—Cyclosporine—psoriasis	8.56e-05	0.000245	CcSEcCtD
Raltegravir—Urticaria—Hydrocortisone—psoriasis	8.55e-05	0.000245	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—psoriasis	8.54e-05	0.000245	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—psoriasis	8.5e-05	0.000244	CcSEcCtD
Raltegravir—Body temperature increased—Hydrocortisone—psoriasis	8.5e-05	0.000243	CcSEcCtD
Raltegravir—Abdominal pain—Hydrocortisone—psoriasis	8.5e-05	0.000243	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—psoriasis	8.49e-05	0.000243	CcSEcCtD
Raltegravir—Asthenia—Mycophenolate mofetil—psoriasis	8.47e-05	0.000243	CcSEcCtD
Raltegravir—Hypertension—Prednisone—psoriasis	8.47e-05	0.000242	CcSEcCtD
Raltegravir—Chills—Methotrexate—psoriasis	8.45e-05	0.000242	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—psoriasis	8.41e-05	0.00432	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Betamethasone—psoriasis	8.37e-05	0.00024	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.37e-05	0.00024	CcSEcCtD
Raltegravir—Pruritus—Mycophenolate mofetil—psoriasis	8.35e-05	0.000239	CcSEcCtD
Raltegravir—Myalgia—Prednisone—psoriasis	8.35e-05	0.000239	CcSEcCtD
Raltegravir—Arthralgia—Prednisone—psoriasis	8.35e-05	0.000239	CcSEcCtD
Raltegravir—Feeling abnormal—Triamcinolone—psoriasis	8.35e-05	0.000239	CcSEcCtD
Raltegravir—Anxiety—Prednisone—psoriasis	8.32e-05	0.000238	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—psoriasis	8.32e-05	0.000238	CcSEcCtD
Raltegravir—Insomnia—Dexamethasone—psoriasis	8.31e-05	0.000238	CcSEcCtD
Raltegravir—Insomnia—Betamethasone—psoriasis	8.31e-05	0.000238	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.29e-05	0.000237	CcSEcCtD
Raltegravir—Diarrhoea—Cyclosporine—psoriasis	8.28e-05	0.000237	CcSEcCtD
Raltegravir—Paraesthesia—Dexamethasone—psoriasis	8.25e-05	0.000236	CcSEcCtD
Raltegravir—Paraesthesia—Betamethasone—psoriasis	8.25e-05	0.000236	CcSEcCtD
Raltegravir—Discomfort—Prednisone—psoriasis	8.25e-05	0.000236	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—psoriasis	8.25e-05	0.000236	CcSEcCtD
Raltegravir—Erythema—Methotrexate—psoriasis	8.2e-05	0.000235	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—psoriasis	8.2e-05	0.000235	CcSEcCtD
Raltegravir—Hypersensitivity—Prednisolone—psoriasis	8.11e-05	0.000232	CcSEcCtD
Raltegravir—Dyspepsia—Dexamethasone—psoriasis	8.09e-05	0.000232	CcSEcCtD
Raltegravir—Dyspepsia—Betamethasone—psoriasis	8.09e-05	0.000232	CcSEcCtD
Raltegravir—Diarrhoea—Mycophenolate mofetil—psoriasis	8.08e-05	0.000231	CcSEcCtD
Raltegravir—Urticaria—Triamcinolone—psoriasis	8.05e-05	0.00023	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—psoriasis	8.03e-05	0.00023	CcSEcCtD
Raltegravir—Body temperature increased—Triamcinolone—psoriasis	8.01e-05	0.000229	CcSEcCtD
Raltegravir—Dizziness—Cyclosporine—psoriasis	8e-05	0.000229	CcSEcCtD
Raltegravir—Decreased appetite—Dexamethasone—psoriasis	7.99e-05	0.000229	CcSEcCtD
Raltegravir—Decreased appetite—Betamethasone—psoriasis	7.99e-05	0.000229	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2S1—psoriasis	7.99e-05	0.0041	CbGpPWpGaD
Raltegravir—Infection—Prednisone—psoriasis	7.95e-05	0.000228	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Betamethasone—psoriasis	7.93e-05	0.000227	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Dexamethasone—psoriasis	7.93e-05	0.000227	CcSEcCtD
Raltegravir—Back pain—Methotrexate—psoriasis	7.93e-05	0.000227	CcSEcCtD
Raltegravir—Hypersensitivity—Hydrocortisone—psoriasis	7.93e-05	0.000227	CcSEcCtD
Raltegravir—Fatigue—Dexamethasone—psoriasis	7.92e-05	0.000227	CcSEcCtD
Raltegravir—Fatigue—Betamethasone—psoriasis	7.92e-05	0.000227	CcSEcCtD
Raltegravir—Pain—Betamethasone—psoriasis	7.86e-05	0.000225	CcSEcCtD
Raltegravir—Pain—Dexamethasone—psoriasis	7.86e-05	0.000225	CcSEcCtD
Raltegravir—Nervous system disorder—Prednisone—psoriasis	7.85e-05	0.000225	CcSEcCtD
Raltegravir—Dizziness—Mycophenolate mofetil—psoriasis	7.81e-05	0.000224	CcSEcCtD
Raltegravir—Skin disorder—Prednisone—psoriasis	7.77e-05	0.000223	CcSEcCtD
Raltegravir—Hyperhidrosis—Prednisone—psoriasis	7.74e-05	0.000222	CcSEcCtD
Raltegravir—Asthenia—Hydrocortisone—psoriasis	7.72e-05	0.000221	CcSEcCtD
Raltegravir—Vomiting—Cyclosporine—psoriasis	7.7e-05	0.00022	CcSEcCtD
Raltegravir—Rash—Cyclosporine—psoriasis	7.63e-05	0.000219	CcSEcCtD
Raltegravir—Dermatitis—Cyclosporine—psoriasis	7.62e-05	0.000218	CcSEcCtD
Raltegravir—Pruritus—Hydrocortisone—psoriasis	7.61e-05	0.000218	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—psoriasis	7.6e-05	0.000218	CcSEcCtD
Raltegravir—Headache—Cyclosporine—psoriasis	7.58e-05	0.000217	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—psoriasis	7.58e-05	0.000217	CcSEcCtD
Raltegravir—Feeling abnormal—Betamethasone—psoriasis	7.57e-05	0.000217	CcSEcCtD
Raltegravir—Feeling abnormal—Dexamethasone—psoriasis	7.57e-05	0.000217	CcSEcCtD
Raltegravir—Gastrointestinal pain—Dexamethasone—psoriasis	7.52e-05	0.000215	CcSEcCtD
Raltegravir—Gastrointestinal pain—Betamethasone—psoriasis	7.52e-05	0.000215	CcSEcCtD
Raltegravir—Vomiting—Mycophenolate mofetil—psoriasis	7.51e-05	0.000215	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—LEP—psoriasis	7.48e-05	0.00384	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APOE—psoriasis	7.48e-05	0.00384	CbGpPWpGaD
Raltegravir—Hypersensitivity—Triamcinolone—psoriasis	7.46e-05	0.000214	CcSEcCtD
Raltegravir—Rash—Mycophenolate mofetil—psoriasis	7.44e-05	0.000213	CcSEcCtD
Raltegravir—Dermatitis—Mycophenolate mofetil—psoriasis	7.44e-05	0.000213	CcSEcCtD
Raltegravir—Headache—Mycophenolate mofetil—psoriasis	7.4e-05	0.000212	CcSEcCtD
Raltegravir—Malaise—Methotrexate—psoriasis	7.39e-05	0.000212	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—psoriasis	7.36e-05	0.000211	CcSEcCtD
Raltegravir—Diarrhoea—Hydrocortisone—psoriasis	7.36e-05	0.000211	CcSEcCtD
Raltegravir—Urticaria—Dexamethasone—psoriasis	7.3e-05	0.000209	CcSEcCtD
Raltegravir—Urticaria—Betamethasone—psoriasis	7.3e-05	0.000209	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Prednisone—psoriasis	7.29e-05	0.000209	CcSEcCtD
Raltegravir—Dizziness—Prednisolone—psoriasis	7.28e-05	0.000209	CcSEcCtD
Raltegravir—Asthenia—Triamcinolone—psoriasis	7.27e-05	0.000208	CcSEcCtD
Raltegravir—Abdominal pain—Dexamethasone—psoriasis	7.27e-05	0.000208	CcSEcCtD
Raltegravir—Body temperature increased—Dexamethasone—psoriasis	7.27e-05	0.000208	CcSEcCtD
Raltegravir—Abdominal pain—Betamethasone—psoriasis	7.27e-05	0.000208	CcSEcCtD
Raltegravir—Body temperature increased—Betamethasone—psoriasis	7.27e-05	0.000208	CcSEcCtD
Raltegravir—Insomnia—Prednisone—psoriasis	7.24e-05	0.000207	CcSEcCtD
Raltegravir—Nausea—Cyclosporine—psoriasis	7.19e-05	0.000206	CcSEcCtD
Raltegravir—Paraesthesia—Prednisone—psoriasis	7.19e-05	0.000206	CcSEcCtD
Raltegravir—Pruritus—Triamcinolone—psoriasis	7.17e-05	0.000205	CcSEcCtD
Raltegravir—Cough—Methotrexate—psoriasis	7.15e-05	0.000205	CcSEcCtD
Raltegravir—Dizziness—Hydrocortisone—psoriasis	7.11e-05	0.000204	CcSEcCtD
Raltegravir—Dyspepsia—Prednisone—psoriasis	7.05e-05	0.000202	CcSEcCtD
Raltegravir—Nausea—Mycophenolate mofetil—psoriasis	7.01e-05	0.000201	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—psoriasis	6.98e-05	0.0002	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—psoriasis	6.98e-05	0.0002	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—psoriasis	6.98e-05	0.0002	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NFKBIA—psoriasis	6.97e-05	0.00357	CbGpPWpGaD
Raltegravir—Decreased appetite—Prednisone—psoriasis	6.96e-05	0.000199	CcSEcCtD
Raltegravir—Rash—Prednisolone—psoriasis	6.94e-05	0.000199	CcSEcCtD
Raltegravir—Dermatitis—Prednisolone—psoriasis	6.94e-05	0.000199	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.93e-05	0.000198	CcSEcCtD
Raltegravir—Fatigue—Prednisone—psoriasis	6.9e-05	0.000198	CcSEcCtD
Raltegravir—Headache—Prednisolone—psoriasis	6.9e-05	0.000198	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—psoriasis	6.89e-05	0.000197	CcSEcCtD
Raltegravir—Constipation—Prednisone—psoriasis	6.84e-05	0.000196	CcSEcCtD
Raltegravir—Vomiting—Hydrocortisone—psoriasis	6.84e-05	0.000196	CcSEcCtD
Raltegravir—Rash—Hydrocortisone—psoriasis	6.78e-05	0.000194	CcSEcCtD
Raltegravir—Dermatitis—Hydrocortisone—psoriasis	6.78e-05	0.000194	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—psoriasis	6.74e-05	0.000193	CcSEcCtD
Raltegravir—Headache—Hydrocortisone—psoriasis	6.74e-05	0.000193	CcSEcCtD
Raltegravir—Dizziness—Triamcinolone—psoriasis	6.7e-05	0.000192	CcSEcCtD
Raltegravir—Infection—Methotrexate—psoriasis	6.65e-05	0.00019	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisone—psoriasis	6.6e-05	0.000189	CcSEcCtD
Raltegravir—Asthenia—Betamethasone—psoriasis	6.59e-05	0.000189	CcSEcCtD
Raltegravir—Asthenia—Dexamethasone—psoriasis	6.59e-05	0.000189	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—psoriasis	6.56e-05	0.000188	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—psoriasis	6.55e-05	0.000188	CcSEcCtD
Raltegravir—Gastrointestinal pain—Prednisone—psoriasis	6.54e-05	0.000187	CcSEcCtD
Raltegravir—Nausea—Prednisolone—psoriasis	6.54e-05	0.000187	CcSEcCtD
Raltegravir—Pruritus—Betamethasone—psoriasis	6.5e-05	0.000186	CcSEcCtD
Raltegravir—Pruritus—Dexamethasone—psoriasis	6.5e-05	0.000186	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—psoriasis	6.5e-05	0.000186	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—psoriasis	6.47e-05	0.000185	CcSEcCtD
Raltegravir—Vomiting—Triamcinolone—psoriasis	6.44e-05	0.000184	CcSEcCtD
Raltegravir—Nausea—Hydrocortisone—psoriasis	6.39e-05	0.000183	CcSEcCtD
Raltegravir—Rash—Triamcinolone—psoriasis	6.39e-05	0.000183	CcSEcCtD
Raltegravir—Dermatitis—Triamcinolone—psoriasis	6.38e-05	0.000183	CcSEcCtD
Raltegravir—Urticaria—Prednisone—psoriasis	6.36e-05	0.000182	CcSEcCtD
Raltegravir—Headache—Triamcinolone—psoriasis	6.35e-05	0.000182	CcSEcCtD
Raltegravir—Abdominal pain—Prednisone—psoriasis	6.33e-05	0.000181	CcSEcCtD
Raltegravir—Body temperature increased—Prednisone—psoriasis	6.33e-05	0.000181	CcSEcCtD
Raltegravir—Diarrhoea—Dexamethasone—psoriasis	6.29e-05	0.00018	CcSEcCtD
Raltegravir—Diarrhoea—Betamethasone—psoriasis	6.29e-05	0.00018	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—psoriasis	6.09e-05	0.000174	CcSEcCtD
Raltegravir—Dizziness—Betamethasone—psoriasis	6.08e-05	0.000174	CcSEcCtD
Raltegravir—Dizziness—Dexamethasone—psoriasis	6.08e-05	0.000174	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—psoriasis	6.05e-05	0.000173	CcSEcCtD
Raltegravir—Nausea—Triamcinolone—psoriasis	6.02e-05	0.000172	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—psoriasis	6.01e-05	0.000172	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—psoriasis	5.95e-05	0.00017	CcSEcCtD
Raltegravir—Hypersensitivity—Prednisone—psoriasis	5.9e-05	0.000169	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—psoriasis	5.89e-05	0.000169	CcSEcCtD
Raltegravir—Vomiting—Betamethasone—psoriasis	5.84e-05	0.000167	CcSEcCtD
Raltegravir—Vomiting—Dexamethasone—psoriasis	5.84e-05	0.000167	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—psoriasis	5.81e-05	0.000166	CcSEcCtD
Raltegravir—Rash—Betamethasone—psoriasis	5.79e-05	0.000166	CcSEcCtD
Raltegravir—Rash—Dexamethasone—psoriasis	5.79e-05	0.000166	CcSEcCtD
Raltegravir—Dermatitis—Betamethasone—psoriasis	5.79e-05	0.000166	CcSEcCtD
Raltegravir—Dermatitis—Dexamethasone—psoriasis	5.79e-05	0.000166	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—psoriasis	5.77e-05	0.000165	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—psoriasis	5.77e-05	0.000165	CcSEcCtD
Raltegravir—Headache—Betamethasone—psoriasis	5.76e-05	0.000165	CcSEcCtD
Raltegravir—Headache—Dexamethasone—psoriasis	5.76e-05	0.000165	CcSEcCtD
Raltegravir—Asthenia—Prednisone—psoriasis	5.74e-05	0.000164	CcSEcCtD
Raltegravir—Pain—Methotrexate—psoriasis	5.72e-05	0.000164	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TYK2—psoriasis	5.71e-05	0.00293	CbGpPWpGaD
Raltegravir—Pruritus—Prednisone—psoriasis	5.66e-05	0.000162	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—psoriasis	5.51e-05	0.000158	CcSEcCtD
Raltegravir—Diarrhoea—Prednisone—psoriasis	5.48e-05	0.000157	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—psoriasis	5.47e-05	0.000157	CcSEcCtD
Raltegravir—Nausea—Betamethasone—psoriasis	5.46e-05	0.000156	CcSEcCtD
Raltegravir—Nausea—Dexamethasone—psoriasis	5.46e-05	0.000156	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—psoriasis	5.31e-05	0.000152	CcSEcCtD
Raltegravir—Dizziness—Prednisone—psoriasis	5.29e-05	0.000152	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—psoriasis	5.29e-05	0.000151	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—psoriasis	5.29e-05	0.000151	CcSEcCtD
Raltegravir—Vomiting—Prednisone—psoriasis	5.09e-05	0.000146	CcSEcCtD
Raltegravir—Rash—Prednisone—psoriasis	5.05e-05	0.000144	CcSEcCtD
Raltegravir—Dermatitis—Prednisone—psoriasis	5.04e-05	0.000144	CcSEcCtD
Raltegravir—Headache—Prednisone—psoriasis	5.01e-05	0.000144	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—psoriasis	4.97e-05	0.00255	CbGpPWpGaD
Raltegravir—Hypersensitivity—Methotrexate—psoriasis	4.93e-05	0.000141	CcSEcCtD
Raltegravir—Asthenia—Methotrexate—psoriasis	4.8e-05	0.000137	CcSEcCtD
Raltegravir—Nausea—Prednisone—psoriasis	4.75e-05	0.000136	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—psoriasis	4.73e-05	0.000136	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL6—psoriasis	4.73e-05	0.00242	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—psoriasis	4.62e-05	0.00237	CbGpPWpGaD
Raltegravir—Diarrhoea—Methotrexate—psoriasis	4.58e-05	0.000131	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NFKB1—psoriasis	4.45e-05	0.00228	CbGpPWpGaD
Raltegravir—Dizziness—Methotrexate—psoriasis	4.42e-05	0.000127	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—psoriasis	4.25e-05	0.000122	CcSEcCtD
Raltegravir—Rash—Methotrexate—psoriasis	4.22e-05	0.000121	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—psoriasis	4.21e-05	0.000121	CcSEcCtD
Raltegravir—Headache—Methotrexate—psoriasis	4.19e-05	0.00012	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—psoriasis	4.04e-05	0.00207	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—psoriasis	4e-05	0.00205	CbGpPWpGaD
Raltegravir—Nausea—Methotrexate—psoriasis	3.97e-05	0.000114	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CARM1—psoriasis	3.9e-05	0.002	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—psoriasis	3.05e-05	0.00156	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—psoriasis	2.79e-05	0.00143	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAT—psoriasis	2.4e-05	0.00123	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOE—psoriasis	1.86e-05	0.000956	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—psoriasis	1.62e-05	0.000833	CbGpPWpGaD
